AAN 2022 | Personalized treatment in migraine prevention

Yi-Chieh Chen, PharmD, Mayo Clinic, Rochester, MN, outlines the importance of personalized treatment in migraine management. Currently, the selection of preventive migraine treatments is a trial and error process, where patients are started on a low dose and titrated up weekly until the minimum effective dose reported in the literature is reached. Using a personalized approach based on genomic or pharmacogenomic factors to understand the best drug and dose for each patient could save valuable time and improve the patient’s quality of life. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.